Biocept's CNSide Cerebrospinal Fluid Assay Featured in Two Oral Presentations At The 2023 SNO/ASCO CNS Cancer Conference
Portfolio Pulse from Happy Mohamed
Biocept, Inc. (NASDAQ:BIOC) announced that its CNSide cerebrospinal fluid assay was featured in two presentations at the 2023 SNO/ASCO CNS Cancer Conference. The presentations highlighted the potential of CNSide in detecting HER2 amplification in patients with solid tumors and leptomeningeal metastasis (LM), and its superiority in detecting leptomeningeal carcinomatosis (LMC) compared to traditional CSF cytology. The results suggest that CNSide could provide valuable information for treatment decision making and potentially improve survival.
August 14, 2023 | 9:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biocept's CNSide assay was featured in two presentations at a major cancer conference, suggesting its potential in improving cancer treatment decision making.
The presentations at the SNO/ASCO CNS Cancer Conference highlighted the potential of Biocept's CNSide assay in detecting HER2 amplification in patients with solid tumors and leptomeningeal metastasis, and its superiority in detecting leptomeningeal carcinomatosis compared to traditional CSF cytology. This suggests that the product could provide valuable information for treatment decision making and potentially improve survival, which could increase demand for the product and positively impact Biocept's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100